M&A Activity • Jan 7, 2014
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 7 January 2014 12:47
Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the Acquisition of Aaren Scientific
Carl Zeiss Meditec AG / Key word(s): Acquisition
07.01.2014 12:47
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the
Acquisition of Aaren Scientific
Jena, 7 January 2014: Carl Zeiss Meditec AG (ISIN: DE0005313704) today
announces the acquisition of the U.S.-based manufacturer of intraocular
lenses (IOLs) Aaren Scientific Inc. (Aaren) headquartered in Ontario,
California. The share purchase agreement to acquire 100% of shares in Aaren
should be signed today. The transaction is expected to close immediately.
Aaren will be incorporated into the strategic business unit Surgical
Ophthalmology of Carl Zeiss Meditec AG, complementing existing IOL sites in
Berlin, Germany and La Rochelle, France.
Aaren has more than two decades worth of experience in manufacturing IOLs
and owns rights in CE and FDA approved material for the manufacturing of
IOLs. Furthermore, the company has a broad range of highly competitive
products. In 2012, Aaren achieved total revenues of approximately USD 20 m,
mainly generated outside of the U.S. Aaren currently has 235 employees. The
majority of shares in the company had previously been owned by private
investment firm James E Sowell Company Inc. of Dallas, Texas, as well as
other investors, including the CEO and co-founder of Aaren Scientific, Rick
Aguilera, who will stay on board with his management team.
The purchase price for 100% of the shares of Aaren Scientific amounts to
USD 70 m in cash on a cash free/debt free basis.
Insertion of an intraocular lens after cataract surgery is the most
commonly performed ophthalmic surgical procedure. While the vast majority
of IOLs implanted to treat cataracts are monofocal lenses, Carl Zeiss
Meditec has especially shaped the market with its multifocal intraocular
lenses. Carl Zeiss Meditec offers cataract surgeons a complete integrated
solution to treat cataracts from diagnosis to surgery and aftercare. About
70% of all cataract patients come in contact with a product of Carl Zeiss
Meditec. The Strategic Business Unit Surgical Ophthalmology has reported
very encouraging growth rates driven by strong demand for innovative IOLs
over the last few years.
Contact for investors
Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
Tel. +49 3641 220-116, E-Mail: [email protected]
Press contact
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss
Meditec AG
Tel. +49 3641 220-331, E-Mail: [email protected]
07.01.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected],[email protected]
Internet: www.meditec.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.